About Leucid Bio
Leucid Bio is a company based in London (United Kingdom) founded in 2014 by John Maher. Leucid Bio has raised $21.54 million across 3 funding rounds from investors including Epidarex Capital, 2Invest AG and Vulpes. The company has 10 employees as of June 30, 2022. Leucid Bio offers products and services including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms. Leucid Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter London, United Kingdom
- Employees 10 as on 30 Jun, 2022
- Founders John Maher
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Leucid Bio Ltd
- Date of Incorporation 27 Nov, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.54 M (USD)
in 3 rounds
-
Latest Funding Round
$16.19 M (USD), Series A
Jun 24, 2021
-
Investors
Epidarex Capital
& 4 more
-
Employee Count
10
as on Jun 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Leucid Bio
Leucid Bio offers a comprehensive portfolio of products and services, including Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms.
Redesigned CAR structure enhances T-cell potency for cancer treatment.
Autologous CAR T-cell product for head and neck cancer patients.
Targets NKG2D ligands in solid tumours and haematological malignancies.
Rapid, scalable method using blood draws for cell therapy.
People of Leucid Bio
Unlock access to complete
Funding Insights of Leucid Bio
Leucid Bio has successfully raised a total of $21.54M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $16.19 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Leucid Bio
Leucid Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Epidarex Capital, 2Invest AG and Vulpes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments in biotechnology, life sciences, and IT are managed by 2Invest AG.
|
Locked | Locked | Locked | |
|
Early-stage tech and offline investments are managed across sectors.
|
Locked | Locked | Locked |
Investor details for Leucid Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Leucid Bio
Investment portfolio details for Leucid Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Leucid Bio
Detailed financials for Leucid Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Leucid Bio Comparisons
Peer comparison for Leucid Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Leucid Bio
Leucid Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Leucid Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Leucid Bio
Complete news archive for Leucid Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Leucid Bio
Leucid Bio was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Leucid Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Artin Moussavi is the current CEO of Leucid Bio.
Leucid Bio is a funded company, having raised a total of $21.54M across 3 funding rounds to date.
As of Jun 30, 2022, the latest employee count at Leucid Bio is 10.
Developer of therapeutics for the treatment of cancers. The company has CAR T-cell therapies which reprogram patients immune cells to recognize and destroy the cancer cells. The drug candidates include LEU-001 and LEU-005 for solid tumors, LEU-004, and LEU-006 for hematological malignancies.
Leucid Bio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Leucid Bio offers Lateral CAR Platform, T4 Immunotherapy, LEU011, and Novel Manufacturing Platforms.
Leucid Bio has 5 investors. Key investors include Epidarex Capital, 2Invest AG, Vulpes, Future Fund, and Sofinnova Partners.
The valuation of Leucid Bio is $44.36M as of Jun 2021.